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ABSTRACT 
The importance of natural product discovery to society is undeniable as natural products 
have seemingly infinite applications, particularly in regard to pharmacological use as 
antibacterial, antifungal, antiparasitic, anticancer and immunosuppressive agents. The 
search for new therapeutics and other new chemical commodities thus grows 
simultaneously with antibiotic resistance and commercial pressure on pharmaceutical 
research. However, the increasingly common phenomenon of natural product rediscovery 
continues to inhibit advancement in this field (1). We contend that the likelihood of 
rediscovery can be predicted by taxonomic distance between the bacteria in question and 
previously studied bacteria. That is, our data supports a correlation between chemical 
diversity and taxonomic distance, and we offer the hopeful perspective that less 
commonly explored genera have outstanding potential for unique natural product 
discovery. Specifically, we have examined the order Myxococcales, a reputable source of 
secondary metabolites. Our findings have been facilitated by the mining of bacterial 
genomes for biosynthetic gene clusters (BGCs), a methodology that has become a critical 
component to natural product discovery as it takes advantage of the increasing number of 
sequenced bacterial genomes available through public databases. By using the BiG-
SCAPE-CORASON platform to generate sequence similarity networks that contain 994 
BGCs identified by antiSMASH from 36 sequenced myxobacteria, we have observed that 
every predicted BGC was specific to one of three current suborders of myxobacteria. The 
analysis of BGCs detected within four additional, draft genomes supports the observation 
that myxobacterial biosynthetic diversity correlates with taxonomic distance and suggests 
the likelihood of rediscovery when targeting previously investigated genera. Further, 822 
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BGCs with no notable homology to characterized clusters within the MIBiG database are 
presented. This survey portrays the biosynthetic diversity of these BGCs and exemplifies 
the potential for natural product discovery from myxobacteria. Herein we report the 
likelihood for rediscovery of known metabolites from bacteria belonging to previously 
explored genera. The results depict significant biosynthetic potential of bacteria 
associated with overlooked taxa within the Myxococcales and possibly other natural 
product-associated bacteria orders.  
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I. INTRODUCTION 
Microbial secondary metabolites 
Microbial natural products are chemical substances produced by bacteria. The natural 
products that are the focus of this study are known as secondary metabolites, because 
they are produced as a result of secondary metabolism and are not necessary for the 
survival of the producing organism but are known to have other biologically 
advantageous functions for the organism in its natural environment. In contrast, primary 
metabolites, such as amino acids, nucleotides, lipids and carbohydrates, are requisite for 
the growth of bacteria.  
 Secondary metabolites, biosynthesized from structurally simple compounds like 
amino acids or glucose, elicit a great amount of scientific attention because of their 
complexity and immense chemical diversity (2). Many secondary metabolites have wide 
ranges of molecular weights, and many exhibit great stereo-complexity, often having a 
high number of stereogenic carbon centers (3). In other words, there is a significant 
number of derivatives that can potentially be generated from these natural products.  
 Microbial secondary metabolites amount to around 50,000 known compounds 
with the two of the more noteworthy contributors being streptomycetes and myxobacteria 
(4, 5). Actinomycetes, the family under which streptomycetes falls, is generally noted to 
be the frontrunner for microbial natural product producers, but myxobacteria have started 
to receive more recognition for being competitive contributors of secondary metabolites 
(6). 
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Myxobacteria 
Bacterivorous myxobacteria, predatory microorganisms ubiquitous to aquatic and soil 
sediments, employ a variety of social and predation strategies, such as the formation of 
fruiting bodies and spores, cooperative swarming, and collective predation on other 
bacteria as well as fungi (7). These relatively sophisticated biological activities not only 
make them effective micropredators but also prolific providers of diverse secondary 
metabolites. In fact, over 100 bioactive secondary metabolites have been discovered from 
many of the taxa within the entire order Myxococcales, which comprises three described 
suborders, 10 families, 29 genera, and 58 species as of June 2018 (8, 9). Dawid reported 
that between 50 and 100% of myxobacteria produce bioactive compounds (10). This 
coupled with the fact that the genome of myxobacteria is around double the size of 
Escherichia coli and around the same as that of the genus Streptomyces, the potential for 
drug discovery through the exploration of myxobacteria is seemingly quite promising (1). 
Traditional methods of natural product discovery 
The methodologies and strategies for natural product discovery have evolved greatly over 
the last century. The first natural product brought to the market was penicillin during 
WWII, but the real search for natural products began with and resulted from the 
Waksman group at the Rutgers lab in the 1940s as they screened actinomycetes from soil 
samples and subsequently discovered actinomycin, streptothricin, and, most significantly, 
streptomycin (3). Pharmaceutical companies began funding research whose focus was 
screening environmental samples of actinomycetes and fungi and testing isolated 
products against test organisms. After acquiring samples containing microorganisms then 
completing the process of detection, fermentation and isolation of secondary metabolites, 
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researchers performed phenotypic screening to test the harnessed products for bioactive 
capabilities (3).   
 Several advancements were made starting in the 1970s and continued into 1990s 
that made this field of research much more efficient, like combinatorial biosynthesis and 
certain target-based approaches (3). Yet, despite such developments and the subjects of 
studies being microorganisms that are generally known to produce bioactive secondary 
metabolites, the results from the aforementioned method of bioactivity-based screening 
have been discouraging in recent years, which is primarily attributed to the tendency of 
this type of approach to rediscover known natural products (11). In fact, rediscovery of 
known compounds has been proclaimed “the bane of natural products discovery” (3). 
Researchers were motivated to explore other means by which to find novel secondary 
metabolites, leading to the popularity of modern genomics-based approaches.   
Genomics in natural product discovery 
Genome-sequencing technology has become widely accessible and inexpensive in recent 
years, leading to a steady increase in the number of bacterial genomes and biosynthetic 
gene clusters (BGCs) publicly available through online databases. Medema and 
coworkers define a BGC as “a physically clustered group of two or more genes in a 
particular genome that together encode a biosynthetic pathway for the production of a 
specialized metabolite (including its chemical variants)” (12). It has become apparent 
through microbial genomics that many microorganisms possess cryptic BGCs, gene 
clusters that encode proteins that control the synthesis of certain secondary metabolites 
but that are not active under laboratory growth conditions (13). By scanning DNA 
sequences, the structures of new secondary metabolites can be predicted, which is 
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especially useful in regard to cryptic BGCs that will not produce these compounds 
without special activation (3).  
Three powerful and complimentary computational tools for BGC identification 
and analysis are antiSMASH (antibiotics & Secondary Metabolite Analysis Shell), BiG-
SCAPE (Biosynthetic Gene Similarity Clustering and Prospecting Engine), and 
CORASON (CORe Analysis of Syntenic Orthologues to prioritize Natural products 
biosynthetic gene clusters) (14, 15). The antiSMASH software tool identifies and predicts 
BGCs, which are then used by BiG-SCAPE to determine gene cluster families (GCFs) 
and generate a sequence similarity network based on these families with the help of the 
MIBiG (Minimum Information about a Biosynthetic Gene cluster) repository that 
contains a large collection of identified BGCs (14, 15). Sequence similarity networks are 
used to depict the relationships among protein sequences, clustering sequences with a 
certain level of homology that can be preemptively specified if desired. Following BiG-
SCAPE analysis, CORASON can be used to perform a phylogenetic analysis that shows 
the evolutionary relationships of BGCs within each GCF (15). The workflow for how 
these software tools all work together is depicted in Fig. 1.  
A genomics-driven analysis of myxobacteria  
Here we present a survey of all myxobacterial natural product BGCs that are included in 
the antiSMASH database and provide documentation of all BGCs with and without 
characterization and assigned metabolites, illustrating the capacity for discovery from 
sequenced myxobacteria. A homology network that contains 994 BGCs from 36 
sequenced myxobacteria was constructed with the use of the BiG-SCAPE/CORASON 
platform (15). Edges between BiG-SCAPE’s rendered GCFs indicate shared domain 
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types, sequence similarity, and similarity of domain pair-types amongst input BGCs (15). 
A comparative analysis against the MIBiG repository (v1.4) demonstrates the great 
amount of BGCs that have not yet been characterized (12).    
 
 
 
Fig 1. The BiG-SCAPE/CORASON workflow (15). 
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II. RESULTS AND DISCUSSION 
BiG-SCAPE analysis of BGCs from sequenced myxobacteria 
Using BiG-SCAPE, we constructed a sequence similarity network that shows homology 
across 735 GCFs, containing 994 total BGCs as unique nodes from 36 myxobacteria and 
includes 1,035 edges (Fig. 2). A total of 613 singletons without significant homology 
using a similarity cutoff of 0.30 were also included in the network to appropriately depict 
all myxobacterial BGCs within the antiSMASH database (14, 16). Predicted BGC classes 
included 64 type I or modular polyketide synthases (t1PKS), 57 PKS categorized by 
antiSMASH as “PKSother” that includes all non-modular categories of PKSs, 125 
nonribosomal peptide synthetases (NRPS), 166 hybrid PKS-NRPS, 245 ribosomally 
synthesized and post-translationally modified peptides (RiPPs), 149 terpenoid clusters, 
three saccharide clusters, and 185 clusters not belonging to any of the aforementioned 
classes that antiSMASH categorizes as “Others” clusters (14, 17). While hybrid PKS-
NRPS pathways that include both PKS and NRPS domains are organized into a specific 
separate grouping, all other hybrid pathways that include more than one BGC are 
categorized in the Others class (14, 15). The Others-associated BGCs included clusters 
with 133 predicted products as well as 52 hybrid BGCs (Fig. 3). This breadth of 
biosynthetic diversity from just 36 myxobacteria includes 23 out of 44 BGC-types 
currently designated by antiSMASH (14, 17).  
Discovered metabolites from myxobacteria and associated BGCs 
Of the 994 BGCs analyzed, 149 possess sequence similarities greater than 75% with 
annotated BGCs in the MIBiG repository (v 1.4) (12). As these BGCs produce 
characterized metabolites or potentially analogues thereof (Fig. 4A), a total of 85% of the  
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Fig. 2 Sequence similarity network of 994 myxobacterial BGCs deposited in the 
antiSMASH database generated by BiG-SCAPE and rendered with Cytoscape. All GCFs 
that include at least one BGC with sequence similarity greater than 75% to a 
characterized cluster deposited in the MIBiG repository are boxed in grey (excluding 23 
geosmin BGCs). Totals for BGC class diversity and GCFs (including geosmin BGCs) 
with homology to MIBiG clusters and color reference provided (right). 
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Fig. 3 Sequence similarity network of myxobacterial BGCs classified as Others in the 
antiSMASH database with predicted product type and totals (right).
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Fig. 4 Secondary metabolites associated with BGCs determined to possess significant 
sequence similarities to characterized clusters in MIBiG (A) and metabolites associated 
with known BGCs from myxobacteria with lower sequence similarities to BGCs included 
in the dataset with (B).
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BGCs within the network produce yet to be discovered metabolites (18-42). Considering 
the range in quality across the 36 total genomes and draft genomes incorporated in the 
antiSMASH database, we also considered additional BGCs with similarity scores lower 
than 75% that had similarities with MIBiG clusters reported from myxobacteria identified 
by antiSMASH. This analysis provided an additional 23 BGCs that might produce 
metabolites with overlapping chemical diversities to the products delineated within the 
MIBiG repository (Fig. 4B) (43-57). Including this inference, 83% of the BGCs within 
the network lack any association with a reported myxobacterial metabolite. The 
biosynthetic diversity of these mapped BCGs includes five t1PKS, 10 NRPS, 37 hybrid 
PKS-NRPS, four PKSother, 28 terpenoid clusters, and 42 Others (Fig. 2). While the vast 
majority of BGCs were considered singletons or unclustered individual nodes without 
sequence similarity to other analyzed BGCs, GCFs with more than one member BGC 
often shared sequence similarities with characterized MIBiG clusters. Interestingly, 
BGCs with high sequence similarity to specific MIBiG clusters were not always assigned 
the same cluster class nor included within an individual GCF. For example, nine GCFs 
that include a single BGC with high homology to the myxochelin BGC were assigned as 
NRPS, hybrid PKS-NRPS, and Others type clusters (32, 33). Trees generated by 
CORASON provide the phylogenetic diversity associated with these myxochelin BGCs 
(Fig. 5) (15). Analysis of these trees indicated that such wholesale affiliation with each of 
these GCFs led to inclusion of BGCs that were in fact not related to the myxochelin BGC 
but instead shared proximal similarity to a BGC within the family that also included a 
neighboring mxyochelin-like BGC (Fig. 5) (32, 33). While this assuredly leads to an 
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Fig. 5 Phylogenetic tree of BGCs included in NRPS GCF (FAM_00603) and Others GCF 
(FAM_00669) generated by CORASON with sequence similarities to the myxochelin 
BGC in MIBiG (BGC0001345) boxed in red and the sequence similarity leading to 
clustering of FAM_00669 boxed in blue. The BGCs boxed in blue are omitted from our 
estimate of unexplored biosynthetic space due to sequence similarities between the 
myxochelin BGC and one BGC within the GCF. This omission typifies our conservative 
estimate of uncharted myxobacterial BGCs. 
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underestimation of the unexplored biosynthetic space as presented, this only supports our 
eventual conclusion that a vast wealth of biosynthetic space from these myxobacteria 
remain unexplored. Other BGCs observed across multi-member GCFs included: 26 
BGCs within 11 GCFs homologous to a carotenoid cluster from Mxyococcus xanthus, 24 
BGCs and four GCFs associated with the characterized VEPE/AEPE/TG-1 biosynthetic 
pathway from M. xanthus DK1622, and 11 BGCs across five GCFs with significant 
similarity to the hybrid PKS-NRPS DKxanthene cluster (18, 19, 23, 24, 42). While all of 
the BGCs included in this charted biosynthetic space might not correlate to the 
corresponding metabolites associated with each MIBiG cluster, we consider this a 
rigorous assessment that provides a conservative estimate of outstanding, uncharacterized 
BGCs and remaining opportunity for natural product discovery. 
Biosynthetic space with undiscovered metabolites 
Perhaps the most obvious absence in the 172 BGCs associated with characterized BGCs, 
no RiPP clusters with significant sequence similarity to MIBiG clusters were observed 
(58-60). However, the recently reported RiPP, crogacin A produced by Chondromyces 
crocatus is the only myxobacterial RiPP discovered to date, and the BGC is currently not 
deposited in the MIBiG repository (61). Also of note, crogacin A possesses a unique 
tetracyclic structure not associated with other classes of RiPPs (61). This combined with 
the 245 uncharacterized BGCs within our network suggests that myxobacteria to be an 
excellent resource for the discovery of RiPPs with novel chemical scaffolds. While 
accounting for far fewer BGCs within the network, no sequence similarities were 
observed for the three saccharide BGCs that include the aminoglycoside and 
aminocyclitol subtypes (62-64). All other BGCs considered unexplored accounted for the 
  13 
vast majority of BGCs within each cluster class including:  92% of t1PKS, 98% of 
PKSother, 92% of NRPS, 81% of terpenoid clusters, 78% of hybrid PKS-NRPS, and 
77% of Others. Interestingly, within the BGCs assigned to the Others class three 
butyrolactone and one homoserine lactone clusters were identified. Specialized 
metabolites belonging to these types of clusters are quorum-signalling molecules 
produced by Streptomyces and numerous non-myxobacterial Proteobacteria respectively 
(65-68). Although putative quorum signal receptors have been observed in myxobacterial 
genomes, no metabolite associated with either of these quorum signalling systems nor 
regulatory process attributed to either’s presence has been reported from a myxobacteria 
(69). 
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IV. EXPERIMENTAL 
Dataset 
All BGCs associated with the order Myxococcales, a total of 994 BGCs from 36 
myxobacteria, were obtained from downloaded as .gbk files from the antiSMASH 
database (https://antismash-db.secondarymetabolites.org) (14). 
BIG-SCAPE-CORASON analysis 
BiG-SCAPE version 20181005 (available at: https://git.wageningenur.nl/medema-
group/BiG-SCAPE) was used locally to analyze the 994 BGCs as individual .gbk 
files downloaded from the antiSMASH database (1/30/2019) (14, 15). BiG-
SCAPE analysis was supplemented with Pfam database version 31 (70). The 
singleton parameter in BiG-SCAPE was toggled to ensure that BGCs with 
distances lower than the default cutoff distance of 0.3 were included in the 
corresponding output data. The MIBiG parameter in BiG-SCAPE was toggled to 
include the MIBiG repository version 1.4 of annotated BGCs (12). The hybrids-off 
parameter was toggled to prevent hybrid BGC redundancy. Generated network 
files separated by BiG-SCAPE class were combined for visualization using 
Cytoscape version 3.7.1; annotations associated with each BGC were included into 
Cytoscape networks by importing curated tables generated by BiG-SCAPE (16). 
All BGCs with sequence similarities to deposited MIBiG clusters greater than 75% 
were indicated and annotated using Cytoscape (16).  
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V. CONCLUSIONS 
The potential benefits associated with the discovery of novel, biologically active bacterial 
metabolites are clear considering their possible applications as antimicrobials or 
anticancer therapeutics. With the insight provided by the excess of available genome data 
from sequenced microbes and the assistance of newly developed and publicly available 
software tools, the search for new bacterial natural products can be steered in the right 
direction toward biosynthetic space that is largely yet to be explored and that belongs to 
gifted producers of secondary metabolites, namely myxobacteria. The vast discrepancies 
between the BGCs of myxobacteria with sequence similarity to characterized pathways 
and BGCs without lend significant credence to the likelihood of continued discovery of 
novel metabolites from just this subset of 36 myxobacteria and exemplifies the 
outstanding potential associated with the Myxococcales at large.  
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